Acerola exosome-like nanovesicles to systemically deliver nucleic acid medicine via oral administration

• Main Authors: Tomohiro Umezu, Masakatsu Takanashi, Yoshiki Murakami, Shin-ichiro Ohno, Kohsuke Kanekura, Katsuko Sudo, Kenichi Nagamine, Shin Takeuchi, Takahiro Ochiya, Masahiko Kuroda
• Format: Article
• Language: English
• Published: Elsevier 2021-06-01
• Series: Molecular Therapy: Methods & Clinical Development
• Subjects: acerola; nanovesicle; nucleic acid medicine; oral administration
• Online Access: http://www.sciencedirect.com/science/article/pii/S2329050121000462

Extracellular vesicles derived from mammalian cells could be useful carriers for drug delivery systems (DDSs); however, with regard to clinical application, there are several issues to be overcome. Acerola (Malpighia emarginata DC.) is a popular health food. In this study, the feasibility of orally administered nucleic acid drug delivery by acerola exosome-like nanoparticles (AELNs) was examined. AELNs were recovered from acerola juice using an affinity column instead of ultracentrifugation. MicroRNA (miRNA) was sufficiently encapsulated in AELNs by 30-min incubation on ice and was protected against RNase, strong acid, and base treatments. The administration of an AELN/miRNA mixture in cells achieved downregulation of the miRNA’s target gene, and this mixture showed cytoplasmic localization. AELNs orally delivered small RNA to the digestive system in vivo. The target gene-suppressing effect in the small intestine and liver peaked 1 day after administration, indicating potential for use as an oral DDS for nucleic acid in the digestive system.